Procedure for submitting applications for marketing vaccines (State control for each batch) for COVID-19

AIFA, at least 6 doses can be obtained from each vial of BioNTech/Pfizer vaccine

Useful information and answers to questions about the COMIRNATY vaccine for COVID-19

AIFA recommendations on hydroxycloroquine

BioNTech/Pfizer vaccine authorised Answers to frequently asked questions on AIFA’s website

Use of Bamlanivimab monoclonal antibody in Italy for the treatment of COVID-19: no free of charge offer from Eli Lilly, just a sale approval request

EMA recommends first COVID-19 vaccine for authorisation in the EU

Update on assessment of marketing authorisation application for Moderna’s mRNA-1273 COVID-19 vaccine

Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application

AIFA establishes the Scientific Committee for monitoring COVID-19 vaccines

Guidelines on the treatment of COVID-19 patients

CTS guidelines on the submission of clinical trials for COVID-19

Web conference "Theft of medicines - Analysis and trends of a complex phenomenon"

EMA starts rolling review of Janssen’s COVID-19 vaccine Ad26.COV2.S

EMA receives application for conditional marketing authorisation of Moderna COVID-19 vaccine

EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2

Norme di igiene e di distanziamento fisico per l’esecuzione delle ispezioni on-site eseguite dall’Ufficio Ispezioni e Autorizzazioni GMP Medicinali

Italian Medicines Agency's Communiction to CRFV / RLFV on the management of reporting adverse reactions to medicines used in COVID-19 therapy - UPDATE

COVID-19: AIFA limits the use of remdesivir in selected cases and allows for hydroxychloroquine to be used only in randomised clinical trials in an outpatient setting

Update on remdesivir - EMA will evaluate new data from Solidarity trial